582 reports of this reaction
2.0% of all OBINUTUZUMAB reports
#11 most reported adverse reaction
ATRIAL FIBRILLATION is the #11 most commonly reported adverse reaction for OBINUTUZUMAB, manufactured by Genentech, Inc.. There are 582 FDA adverse event reports linking OBINUTUZUMAB to ATRIAL FIBRILLATION. This represents approximately 2.0% of all 28,651 adverse event reports for this drug.
Patients taking OBINUTUZUMAB who experience atrial fibrillation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ATRIAL FIBRILLATION is a less commonly reported adverse event for OBINUTUZUMAB, but still significant enough to appear in the safety profile.
In addition to atrial fibrillation, the following adverse reactions have been reported for OBINUTUZUMAB:
The following drugs have also been linked to atrial fibrillation in FDA adverse event reports:
ATRIAL FIBRILLATION has been reported as an adverse event in 582 FDA reports for OBINUTUZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ATRIAL FIBRILLATION accounts for approximately 2.0% of all adverse event reports for OBINUTUZUMAB, making it a notable side effect.
If you experience atrial fibrillation while taking OBINUTUZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.